EP Patent
EP3341375B1 — Process for preparing parp inhibitor, crystalline forms, and uses thereof
Assigned to BeOne Medicines Ltd · Expires 2022-04-13 · 4y expired
What this patent protects
Patent listed against Talzenna.
Drugs covered by this patent
- Talzenna (Talazoparib Tosylate) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.